Royalty Pharma plc Class A Ordinary Shares RPRX
$57.99
-0.51%
at last close
Market Cap$25.96 billion
P/E Ratio30.85
Div Yield1.62%
Volume384.1K
52-Week Range
$34.08$64.38
Analyst Ratings
- Consensus
- Buy — 6 Buy · 0 Hold · 0 Sell (6 analysts)
- Avg. Price Target
- $59.67 (+2.9% upside)
Key Stats
- Today's Range
- $57.68 – $58.50
- 50-Day Range
- $56.36 – $64.38
- 52-Week Range
- $34.08 – $64.38
- Volume
- 384K shs
- Average Volume
- 2.90 million shs
- Market Cap
- $25.96 billion
- P/E Ratio
- 30.85
- Dividend Yield
- 1.62%
Valuation
- P/E Ratio
- 30.85
- Price / Book
- 2.65
- Price / Sales
- 10.23
Dividend
- Dividend Yield
- 1.62%
- Annual Dividend
- $0.94
- Payout Ratio
- 50.00%
- Ex-Dividend Date
- 2026-08-14
Short Interest
- Short Interest
- 0.34%
- Days to Cover
- 2.12
Financials (TTM)
- Revenue
- $2.54 billion
- Net Income
- $1.35 billion
- Net Margin
- 53.23%
- Return on Equity
- 13.79%
- Debt-to-Equity
- 0.92
About Royalty Pharma plc Class A Ordinary Shares
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
Related Stocks
Compare head-to-head: RPRX vs LLY·RPRX vs JNJ·RPRX vs ABBV·RPRX vs ABT
Price and fundamental data are delayed and provided for informational purposes only. Not investment advice. See our disclaimer.